Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer Source: Eur Respir Rev, 28 (153) 190058; 10.1183/16000617.0058-2019 Year: 2019
A case of pulmonary tuberculosis development after receiving immune check point inhibitor in an advanced non-small cell lung cancer Source: International Congress 2019 – Lung cancer? Year: 2019
Impact of antibiotics on immunotherapy response in lung cancer patients Source: International Congress 2019 – Treatment of lung cancer Year: 2019
How to manage immune-related adverse effects in lung cancer patients under immunotherapy Source: CME Online 2019 Year: 2018
Lung disease induced by newer therapies for lung cancer: an update Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006
Immune checkpoint inhibitors in lung cancer Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine Year: 2016
Immune checkpoint inhibitor-associated interstitial lung diseases: some progress but still many issues Source: Eur Respir J, 50 (2) 1701319; 10.1183/13993003.01319-2017 Year: 2017
Influenza and Pneumococcal vaccination effects on the immune-related adverse events in patients under immunotherapy for an advanced stage non-small cell lung cancer Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021
Checkpoint inhibition (neo-)adjuvant therapy in early stage lung cancer: the oncological evidence Source: Virtual Congress 2021 – Hot topics in thoracic oncology Year: 2021
Evaluation of tuberculosis risk in patients submitted to chronic immunosuppressive therapy for osteoarticular immune disease Source: Eur Respir J 2006; 28: Suppl. 50, 131s Year: 2006
Pneumococcal vaccination in interstitial lung disease patients receiving systemic immunosuppressive treatment Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis Year: 2017
From ineffective tumor immune response to immunomodulation in lung cancer Source: ERS Research Seminar 2017 – Immunotherapy: a new standard of care in thoracic malignancies? Year: 2017
Are biphosphonates efficient in the adjuvant treatment of lung cancer? Source: Eur Respir J 2006; 28: Suppl. 50, 754s Year: 2006
How to evaluate the immune status of lung cancer patients before immunotherapy Source: Breathe, 13 (4) 291; 10.1183/20734735.001917 Year: 2017
The role of radiation therapy in the management of small cell lung cancer Source: Breathe, 13 (4) e87; 10.1183/20734735.009617 Year: 2017
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients Source: Eur Respir J, 50 (2) 1700050; 10.1183/13993003.00050-2017 Year: 2017
Accompanying diseases in lung cancer patients Source: Eur Respir J 2006; 28: Suppl. 50, 127s Year: 2006
Management of pulmonary toxicity associated with immune checkpoint inhibitors Source: Eur Respir Rev, 28 (154) 190012; 10.1183/16000617.0012-2019 Year: 2019
Characteristics, incidence, risk factors, and practical management of pneumonitis associated with anti-PD-1 immunotherapy in patients with non-small cell lung cancer Source: International Congress 2019 – Treatment of lung cancer Year: 2019
Effect of autoimmune diseases on risk and survival in histology-specific lung cancer Source: Eur Respir J 2012; 40: 1489-1495 Year: 2012